ObesityWeek attendees crowd around a poster with Phase 1 data for Viking's oral weight loss drug VK2735. (Credit: Kyle LaHucik for Endpoints News)

November 3, 2024 09:18 PM ESTUpdated 06:28 AM

Pharma

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Kyle LaHucik

Senior Reporter

SAN ANTONIO — Viking Therapeutics’ highly anticipated readout of its oral anti-obesity pill showed a placebo-adjusted weight loss of 6.8% after four weeks, sticking the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial